sellWeak cluster of 210b5-1 plan
Jane Henderson sold $120k of APGE
Chief Financial Officer at Apogee Therapeutics, Inc.. 1,500 shares at an average of $80.00, traded Dec 19, 2025, filed Dec 23, 2025.
Warning score
20Value
$120k
1,500 shares
Holdings after
193,371
-1% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +22RoleCFO
- +10Trade size$120k at market
- 0Share of holdings soldSold 0.8% of holdings
- +8Cluster2 insiders selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0001104659-25-124354, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Dec 19, 2025 | SOpen-market sale Common Stock10b5-1 | -1,500 | $80.00 | $120k | 193,371 | Dec 23, 2025 |
Related signals
Other insiders at Apogee Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 45Moderate | Apogee Therapeutics, Inc. | Michael Thomas Henderson Chief Executive Officer | $1.5M 20,000 shares | -2% | |
| 45Moderate | Apogee Therapeutics, Inc. | Michael Thomas Henderson Chief Executive Officer | $3.0M 40,000 shares | -3% | |
| 27Weak | Apogee Therapeutics, Inc. | Jane Henderson Chief Financial Officer | $113k 1,500 shares | -1% | |
| 32Weak | Apogee Therapeutics, Inc. | Carl Dambkowski Chief Medical Officer | $818k 10,900 shares | -4% | |
| 27Weak | Apogee Therapeutics, Inc. | Jane Henderson Chief Financial Officer | $105k 1,500 shares | -1% | |
| 28Weak | Apogee Therapeutics, Inc. | Jane Henderson Chief Financial Officer | $130k 2,000 shares | -1% | |
| 45Moderate | Apogee Therapeutics, Inc. | Michael Thomas Henderson Chief Executive Officer | $1.3M 20,000 shares | -2% | |
| 24Weak | Apogee Therapeutics, Inc. | Jane Henderson Chief Financial Officer | $60k 1,000 shares | -0% | |
| 14Weak | Apogee Therapeutics, Inc. | Carl Dambkowski Chief Medical Officer | $594k 10,785 shares | -4% | |
| 0Weak | Apogee Therapeutics, Inc. | Carl Dambkowski Chief Medical Officer | $203k 5,110 shares | -2% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.